{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:36:43Z","timestamp":1787978203784,"version":"build-2784847793"},"reference-count":69,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is an aggressive clonal hematopoietic malignancy, characterized by marked biological heterogeneity and variable clinical outcomes. Among its rarer genetic subsets is AML with rearrangements of the MDS1 and EVI1 complex locus (MECOM), occurring in fewer than 2% of newly diagnosed cases. This review examines the biology and clinical significance of MECOM-rearranged AML, with a focus on its diverse mechanisms of leukemogenesis, including chromosomal inversion and translocation involving 3q26. We discuss how aberrant EVI1\/MECOM activity alters gene expression networks and drives malignant transformation. Current therapeutic approaches\u2014including intensive chemotherapy, hypomethylating agents in combination with venetoclax, and allogeneic stem cell transplantation\u2014are evaluated with particular emphasis on inv(3) and other t(3q26) subtypes. Despite these treatment strategies, outcomes remain poor, underscoring the urgent need for novel, more effective therapies for this high-risk form of AML.<\/jats:p>","DOI":"10.3390\/hematolrep17060059","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T18:21:46Z","timestamp":1762194106000},"page":"59","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["MECOM-Rearranged Acute Myeloid Leukemia: Pathobiology and Management Strategies"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-5846","authenticated-orcid":false,"given":"Utsav","family":"Joshi","sequence":"first","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"\u017du\u010denka, A., and Tamutyt\u0117, M. (2025). Case Report: Decitabine and venetoclax sequentially followed by FLAG-Ida and venetoclax with immediate allogeneic stem cell transplantation in newly diagnosed acute myeloid leukemia with chromosome 3 inversion\/MECOM rearrangement. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1530852"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mikkilineni, S., Pineda-Reyes, J.P., Wilde, L., Ferber, A., Wang, Z.X., Peiper, S., Uppal, G., Gong, J., and Liu, J. (2025). Case Report: Myeloid neoplasms with the t(3;12)(q26.2;p13.1)\/MECOM-ETV6 translocation: Report of two new cases and review of the literature. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1526044"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2217\/fon.15.64","article-title":"3q26\/EVI1 rearrangements in myeloid hemopathies: A cytogenetic review","volume":"11","author":"Basinko","year":"2015","journal-title":"Future Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1038\/bcj.2014.10","article-title":"Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: The Swedish population-based experience","volume":"4","author":"Lazarevic","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1182\/blood-2023-180100","article-title":"Clinical Characteristics and Outcomes of Myeloid Neoplasms with Mecom Rearrangement: Results from a Nationwide Multicenter Study","volume":"142","author":"Polprasert","year":"2023","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/ajh.24099","article-title":"Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities","volume":"90","author":"Wanquet","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.3324\/haematol.2017.178723","article-title":"MDS1 and EVI1 complex locus (MECOM): A novel candidate gene for hereditary hematological malignancies","volume":"103","author":"Ripperger","year":"2018","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/sj.emboj.7600679","article-title":"Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression","volume":"24","author":"Yuasa","year":"2005","journal-title":"EMBO J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/jmedgenet-2012-100990","article-title":"Deletion of the 3q26 region including the EVI1 and MDS1 genes in a neonate with congenital thrombocytopenia and subsequent aplastic anaemia","volume":"49","author":"Nielsen","year":"2012","journal-title":"J. Med. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Pastoors, D., Havermans, M., Mulet-Lazaro, R., Smeenk, L., Ottema, S., Erpelinck-Verschueren, C., van Herk, S., Anthonissen, M., Grob, T., and Subramanian, S. (2025). MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia. bioRxiv, bioRxiv:2025.01.02.631046.","DOI":"10.1101\/2025.01.02.631046"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjh.13898","article-title":"Review: Aberrant EVI 1 expression in acute myeloid leukaemia","volume":"172","author":"Hinai","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1038\/s41467-018-06208-y","article-title":"EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription","volume":"9","author":"Ayoub","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood.2022016592","article-title":"EVI1 drives leukemogenesis through aberrant ERG activation","volume":"141","author":"Schmoellerl","year":"2023","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1158\/0008-5472.CAN-06-3962","article-title":"Repression of RUNX1 Activity by EVI1: A New Role of EVI1 in Leukemogenesis","volume":"67","author":"Senyuk","year":"2007","journal-title":"Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1182\/blood-2009-12-261602","article-title":"Evi1 represses PTEN expression and activates PI3K\/AKT\/mTOR via interactions with polycomb proteins","volume":"117","author":"Yoshimi","year":"2011","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.4049\/jimmunol.1103527","article-title":"EVI1 Acts as an Inducible Negative-Feedback Regulator of NF-\u03baB by Inhibiting p65 Acetylation","volume":"188","author":"Xu","year":"2012","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood.V97.9.2815","article-title":"The corepressor CtBP interacts with Evi-1 to repress transforming growth factor \u03b2 signaling","volume":"97","author":"Izutsu","year":"2001","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"104025","DOI":"10.1016\/j.dib.2019.104025","article-title":"Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies","volume":"24","author":"Tang","year":"2019","journal-title":"Data Brief."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","article-title":"A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia","volume":"157","author":"Sanders","year":"2014","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccr.2014.02.008","article-title":"A Remote GATA2 Hematopoietic Enhancer Drives Leukemogenesis in inv(3)(q21;q26) by Activating EVI1 Expression","volume":"25","author":"Yamazaki","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41408-021-00457-9","article-title":"EVI1 dysregulation: Impact on biology and therapy of myeloid malignancies","volume":"11","author":"Birdwell","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","article-title":"Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)\/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia","volume":"28","author":"Lugthart","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"106387","DOI":"10.1016\/j.leukres.2020.106387","article-title":"MECOM rearrangement involving the MYC locus: Two additional patients with the rare translocation, t(3;8)(q26.2;q24), and molecular review","volume":"95","author":"Smith","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood.V88.2.682.bloodjournal882682","article-title":"Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): A recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes","volume":"88","author":"Raynaud","year":"1996","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1038\/sj.onc.1205356","article-title":"The t(3;21) fusion product, AML1\/Evi-1 blocks AML1-induced transactivation by recruiting CtBP","volume":"21","author":"Izutsu","year":"2002","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"De Weer, A., Poppe, B., Vergult, S., Van Vlierberghe, P., Petrick, M., De Bock, R., Benoit, Y., Noens, L., De Paepe, A., and Van Roy, N. (2010). Identification of Two Critically Deleted Regions within Chromosome Segment 7q35-q36 in EVI1 Deregulated Myeloid Leukemia Cell Lines. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0008676"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/leu.2011.5","article-title":"The inv(3)(q21q26)\/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: A study in 39 cases of MDS or AML","volume":"25","author":"Haferlach","year":"2011","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1182\/blood-2014-07-591529","article-title":"EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations","volume":"125","author":"Gendron","year":"2015","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"E326","DOI":"10.1002\/ajh.25991","article-title":"Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)\/t(3;3)","volume":"95","author":"Sasaki","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood.V126.23.1372.1372","article-title":"Prognosis of Mecom(EVI1)-rearranged MDS and AML Patients Strongly Depends on Accompanying Molecular Mutations but Not on Blast Counts","volume":"126","author":"Alpermann","year":"2015","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Jen, W., Tang, G., Kugler, E., Croden, J., Sasaki, K., Bazinet, A., Bataller, A., Montalban-Bravo, G., Borthakur, G., and Toruner, G.A. (2025). MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia. Br. J. Haematol.","DOI":"10.1111\/bjh.70171"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/gcc.23004","article-title":"Comparison of myeloid neoplasms with nonclassic 3q26.2\/MECOM versus classic inv(3)\/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation","volume":"61","author":"Gao","year":"2022","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Tang, Z., Wang, W., Yang, S., El Achi, H., Fang, H., Nahmod, K.A., Toruner, G.A., Xu, J., Thakral, B., and Ayoub, E. (2023). 3q26.2\/MECOM Rearrangements by Pericentric Inv(3): Diagnostic Challenges and Clinicopathologic Features. Cancers, 15.","DOI":"10.3390\/cancers15020458"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Tsien, F. (2020). Cytogenetics in precision medicine. Clinical Precision Medicine, Elsevier.","DOI":"10.1016\/B978-0-12-819834-6.00001-X"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cancergen.2021.12.009","article-title":"Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies","volume":"262\u2013263","author":"Zhao","year":"2022","journal-title":"Cancer Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/gcc.21992","article-title":"Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases","volume":"51","author":"Haferlach","year":"2012","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cancergen.2014.02.010","article-title":"Amplification of EVI1 on cytogenetically cryptic double minutes as new mechanism for increased expression of EVI1","volume":"207","author":"Volkert","year":"2014","journal-title":"Cancer Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/ejh.13417","article-title":"Acute myeloid leukemia with inv(3)(q21.3q26.2)\/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols","volume":"105","author":"Sitges","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clml.2019.09.615","article-title":"Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia with Recurrent Genetic Abnormalities\u2014AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM","volume":"20","author":"Merz","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e19078","DOI":"10.1200\/JCO.2023.41.16_suppl.e19078","article-title":"Predictors of survival outcomes in patients with MECOM EVI1 rearrangement aberrations in AML or MDS","volume":"41","author":"Kusne","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1182\/blood-2023-186672","article-title":"Acute Myeloid Leukemia with Inv(3) or t(3;3): A Clinical and Cytogenetic Characterization of 40 Patients","volume":"142","author":"Moscvin","year":"2023","journal-title":"Blood"},{"key":"ref_48","first-page":"2331","article-title":"Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)","volume":"108","author":"Rausch","year":"2023","journal-title":"Haematologica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S503","DOI":"10.1016\/S2152-2650(25)01812-9","article-title":"AML-1357: Outcomes in Acute Myeloid Leukemia with MECOM Rearrangement (MECOMr-AML) Treated with Hypomethylating Agent Plus Venetoclax","volume":"25","author":"Boussi","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1016\/j.clml.2020.03.005","article-title":"Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities","volume":"20","author":"Sallman","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood-2010-04-281337","article-title":"Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1","volume":"117","author":"Lugthart","year":"2011","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.V120.21.2594.2594","article-title":"Prognostic Impact of 3q21 and 3q26 Cytogenetic Abnormalities in Acute Myeloid Leukemia","volume":"120","author":"Annunziata","year":"2012","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41409-018-0165-x","article-title":"AlloHSCT for inv(3)(q21;q26)\/t(3;3)(q21;q26) AML: A report from the acute leukemia working party of the European society for blood and marrow transplantation","volume":"53","author":"Halaburda","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Ouyang, X., Wu, X., Hu, S., Jiang, W., Guo, Y., and Huang, Y. (2025). The demographic characteristics and prognosis of acute myeloid leukemia with t(3;3)\/inv(3) in the united states: A SEER-based study. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-95783-4"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1080\/10428194.2020.1737689","article-title":"Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count","volume":"61","author":"Summerer","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1080\/10428190701632848","article-title":"Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)\/t(3;3) (q21;q26) positive AML","volume":"48","author":"Weisser","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.2019003701","article-title":"Atypical 3q26\/MECOM rearrangements genocopy inv(3)\/t(3;3) in acute myeloid leukemia","volume":"136","author":"Ottema","year":"2020","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1158\/1538-7445.AM2024-1687","article-title":"Abstract 1687: Targeted degradation of MECOM in high-risk acute myeloid leukemia reveals a novel repressive function that is amenable to therapeutic small-molecule rewiring","volume":"84","author":"Fleming","year":"2024","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"26028","DOI":"10.1021\/jacs.3c06179","article-title":"Bifunctional Small Molecules That Induce Nuclear Localization and Targeted Transcriptional Regulation","volume":"145","author":"Gibson","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41375-023-02108-3","article-title":"Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression","volume":"38","author":"Birdwell","year":"2024","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41375-018-0334-3","article-title":"Targeting nuclear \u03b2-catenin as therapy for post-myeloproliferative neoplasm secondary AML","volume":"33","author":"Saenz","year":"2019","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1182\/blood-2024-206206","article-title":"Efficacy of Combinations of Targeted Agents Against Dependencies in Mecom Rearranged AML Identified By Unbiased Chemical and CRISPR Screens","volume":"144","author":"Birdwell","year":"2024","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2019-122540","article-title":"Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939","volume":"134","author":"Humbert","year":"2019","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2019-127143","article-title":"In Vivo Assessment of the Next Generation Microtubule-Destabilizing Agent AB8939 in Patient-Derived Xenograft Models of Acute Myeloid Leukemia","volume":"134","author":"Goubard","year":"2019","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2019-127021","article-title":"AB8939, a Microtubule-Destabilizing Agent with Potential to Overcome Multidrug Resistance, Is Active across the Range (M0\u2013M7) of Acute Myeloid Leukemia Subtypes","volume":"134","author":"Goubard","year":"2019","journal-title":"Blood"},{"key":"ref_66","unstructured":"AB Science (2024). AB Science Provides an Update on the Microtubule Program AB8939 and in Particular the Ability of AB8939 to Generate Response on MECOM Rearrangement [press release], AB Science. Available online: https:\/\/www.ab-science.com\/wp-content\/uploads\/2024\/09\/CP-AB8939-Update.-VENG-VF.pdf."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41375-021-01235-z","article-title":"Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia","volume":"35","author":"Kiehlmeier","year":"2021","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"100696","DOI":"10.1016\/j.blre.2020.100696","article-title":"PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias","volume":"45","author":"Fritz","year":"2021","journal-title":"Blood Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1158\/1538-7445.AM2025-451","article-title":"Abstract 451: Superior preclinical efficacy of BRG1\/BRM inhibitor combined with BET inhibitor or decitabine against MECOM-rearranged AML","volume":"85","author":"Fiskus","year":"2025","journal-title":"Cancer Res."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/6\/59\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T19:04:08Z","timestamp":1762196648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/6\/59"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":69,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["hematolrep17060059"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep17060059","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]}}}